Esposito Pasquale, Russo Elisa, Picciotto Daniela, Cappadona Francesca, Battaglia Yuri, Traverso Giovanni Battista, Viazzi Francesca
Unit of Nephrology, Dialysis and Transplantation, Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy.
IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
J Clin Med. 2022 Jun 10;11(12):3349. doi: 10.3390/jcm11123349.
To evaluate the impact of the Coronavirus Disease-19 (COVID-19) pandemic on the epidemiology of acute kidney injury (AKI) in hospitalized patients, we performed a retrospective cohort study comparing data of patients hospitalized from January 2016 to December 2019 (pre-COVID-19 period) and from January to December 2020 (COVID-19 period, including both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-negative and positive patients). AKI was classified by evaluating the kinetics of creatinine levels. A total of 51,681 patients during the pre-COVID-19 period and 10,062 during the COVID-19 period (9026 SARS-CoV-2-negative and 1036 SARS-CoV-2-positive) were analyzed. Patients admitted in the COVID-19 period were significantly older, with a higher prevalence of males. In-hospital AKI incidence was 31.7% during the COVID-19 period (30.5% in SARS-CoV-2-negative patients and 42.2% in SARS-CoV-2-positive ones) as compared to 25.9% during the pre-COVID-19 period (p < 0.0001). In the multivariate analysis, AKI development was independently associated with both SARS-CoV-2 infection and admission period. Moreover, evaluating the pre-admission estimated glomerular filtration rate (eGFR) we found that during the COVID-19 period, there was an increase in AKI stage 2−3 incidence both in patients with pre-admission eGFR < 60 mL/min/1.73 m2 and in those with eGFR ≥ 60 mL/min/1.73 m2 (“de novo” AKI). Similarly, clinical outcomes evaluated as intensive care unit admission, length of hospital stay, and mortality were significantly worse in patients admitted in the COVID-19 period. Additionally, in this case, the mortality was independently correlated with the admission during the COVID-19 period and SARS-CoV-2 infection. In conclusion, we found that during the COVID-19 pandemic, in-hospital AKI epidemiology has changed, not only for patients affected by COVID-19. These modifications underline the necessity to rethink AKI management during health emergencies.
为评估新型冠状病毒肺炎(COVID-19)大流行对住院患者急性肾损伤(AKI)流行病学的影响,我们进行了一项回顾性队列研究,比较了2016年1月至2019年12月(COVID-19大流行前时期)和2020年1月至12月(COVID-19时期,包括严重急性呼吸综合征冠状病毒2(SARS-CoV-2)阴性和阳性患者)住院患者的数据。通过评估肌酐水平的变化情况对AKI进行分类。共分析了COVID-19大流行前时期的51681例患者和COVID-19时期的10062例患者(9026例SARS-CoV-2阴性患者和1036例SARS-CoV-2阳性患者)。COVID-19时期入院的患者年龄显著更大,男性患病率更高。COVID-19时期的院内AKI发病率为31.7%(SARS-CoV-2阴性患者为30.5%,SARS-CoV-2阳性患者为42.2%),而COVID-19大流行前时期为25.9%(p<0.0001)。在多变量分析中,AKI的发生与SARS-CoV-2感染和入院时期均独立相关。此外,评估入院前估计肾小球滤过率(eGFR)时,我们发现COVID-19时期,入院前eGFR<60 mL/min/1.73 m2的患者以及eGFR≥60 mL/min/1.73 m2的患者(“新发”AKI)中,2-3期AKI的发病率均有所增加。同样,以入住重症监护病房、住院时间和死亡率评估临床结局时,COVID-19时期入院的患者明显更差。此外,在这种情况下,死亡率与COVID-19时期入院和SARS-CoV-2感染独立相关。总之,我们发现COVID-19大流行期间,院内AKI的流行病学发生了变化,不仅是受COVID-19影响的患者。这些变化突显了在卫生紧急情况期间重新思考AKI管理的必要性。